Méhnyakrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

42+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 493 450 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 6 602 445 EUR· until 2029. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spanyolország· EU contribution 3 613 288 EUR· until 2028. máj.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Izrael· EU contribution 1 996 250 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norvégia· EU contribution 7 984 441 EUR· until 2027. aug.· 6 countries

5 of 6 running projects, newest first. Listed amounts together: 23,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Frissítve: 2026. jún. 4.

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  NCT03894215· Agenus Inc.· Frissítve: 2026. márc. 27.

  “Sponsor strategic decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Frissítve: 2026. jan. 12.

  “Business Decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial

  NCT06866951· Women's Hospital School Of Medicine Zhejiang University· Frissítve: 2025. dec. 16.

  “no participants enrolled”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

  NCT04042116· Clovis Oncology, Inc.· Frissítve: 2022. dec. 20.

  “Company decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

  NCT04806945· Shanghai Henlius Biotech· Frissítve: 2022. máj. 5.

  “The sponsor terminated the trial.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Merck Sharp & Dohme LLC· Forrás

• Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· Merck Sharp & Dohme LLC· Forrás

• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Merck Sharp & Dohme LLC· Forrás

• A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

  NCT04708470· National Cancer Institute (NCI)· Forrás

• A Study of Ivonescimab in People With Endometrial and Cervical Cancers

  NCT06925724· Memorial Sloan Kettering Cancer Center· Forrás

• Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

  NCT03635567· Merck Sharp & Dohme LLC· Forrás

• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

  NCT02628067· Merck Sharp & Dohme LLC· Forrás

• Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

  NCT04646005· Regeneron Pharmaceuticals· Forrás

• Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

  NCT04516616· Huazhong University of Science and Technology· Forrás

• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

  NCT04042116· Clovis Oncology, Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Molecular Determinants of Treatment Resistance in Cervical Cancer: A Systematic Review and Integrative Bioinformatic Analysis of Publicly Available Datasets.

  Med Sci Monit, 2026. nov.

• Nucleotide metabolism and cervical cancer: A comprehensive study of molecular subtypes and therapeutic targets.

  Medicine (Baltimore), 2026. nov.

• Discovery-locked cross-platform evaluation of a cervical epithelial transcriptional state.

  Funct Integr Genomics, 2026. nov.

• Attentive interpretable tabular learning (TabNet) for miRNA expression classification in cervical cancer and Alzheimer's disease.

  BMC Bioinformatics, 2026. okt.

• Necroptosis as a key player in cervical cancer progression and management: a systematic review and transcriptomic cross-study consensus analysis.

  Apoptosis, 2026. okt.

• Prediction of prognosis and treatment effect of cervical cancer by immunogenic cell death-related genes.

  PeerJ, 2026. okt.

• Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients.

  PLoS Biol, 2026. okt.

• Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated with Clinical Activity.

  Clin Cancer Res, 2026. okt.

• Integrating scRNA-Seq and Spatial Transcriptomics Reveal Novel Risk Stratification Signatures in Cervical Carcinoma.

  J Med Virol, 2026. okt.

• Deciphering the role of microplastics-related molecular signatures in cervical cancer progression: Transcriptomic analysis and diagnostic model development.

  Biochem Biophys Res Commun, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.